Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study: [18F]DCFPyL PET/MRI for Personalizing Prostate Cancer Subclinical Metastatic Ablative MR-guided Radiotherapy (MRgRT)

NCT03160794 is registered in ClinicalTrials.gov with University Health Network, Toronto as lead sponsor.

NCT NCT03160794
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03160794 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study: [18F]DCFPyL PET/MRI for Personalizing Prostate Cancer Subclinical Metastatic Ablative MR-guided Radiotherapy (MRgRT)
Lead sponsor
University Health Network, Toronto
Phase
Not applicable
Overall status
Completed
Start date
May 23, 2017
Completion date
April 1, 2025
Enrollment
150 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

post prostatectomy